ePoster

All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Title:

Performance comparative of new monofocal IOL with enhanced features for intermediate vision to current standard monofocal lens

Poster Details

First Author: D. Teenan UK

Co Author(s):    J. Venter   S. Hannan                 

Abstract Details

Purpose:

To compare the clinical and patient reported outcomes of a new TECNIS Eyhance ICB00 monofocal IOL with enhanced features for intermediate vision to a standard TECNIS ZCB00 monofocal intraocular lens

Setting:

Private Refractive Surgery (Optical Express)

Methods:

Data was reviewed on presbyopic patients who underwent cataract surgery or refractive lens exchange with either TECNIS Eyhance ICB00 monofocal, n=56 patients, or standard TECNIS ZCB00 monofocal IOL, n=146 patients. Treatments were completed between October 2019 through October 2020. Patient age range was 40 to 85 years, with a preop refractive range of +6.00D to -11.00D sphere and up to -3.00D of astigmatism. Postoperative clinical safety and efficacy outcomes up to 12 months following implant were analysed.

Results:

Postoperative UCDVA was -0.05 logMAR and 0.00 logMAR for the ICB00 and ZCB00, respectively. UCDVA of 20/20 or better was achieved in 91.1% of ICB00 patients compared to 76.0% ZCB00 (p=0.0163). Postoperative UCIVA was +0.46 logMAR and +0.55 logMAR for ICB00 and ZCB00, respectively. ICB00 exhibited a mean gain of 9 lines UCDVA, while ZCB00 patients gained 8 lines. UCIVA gain was 6 and 5 lines for Eyhance ICB00 and ZCB00, respectively. Patient reported satisfaction was high for both cohorts at 91.2% and 93.7%, respectively (p>0.05). Reported difficulty with glare, halo or starburst was comparable between IOLs (p>0.05).

Conclusions:

The new TECNIS Eyhance ICB00 provides a safe and effective monofocal intraocular lens option. Performance is comparable to standard monofocal lens with some improvement to UCDVA and UCIVA within the first year. Patient reported satisfaction is also high postoperatively for TECNIS Eyhance ICB00. A larger sample size with longer follow-up is warranted.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation